Cantor Fitzgerald initiated coverage of Entrada Therapeutics (TRDA) with an Overweight rating.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Entrada Therapeutics management to meet with Oppenheimer
- Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics
- Entrada Therapeutics price target raised to $19 from $13 at Roth Capital
- Entrada Therapeutics reports Q4 EPS (94c), consensus ($1.24)
- Advancing DMD and DM1 Pipeline Positions Entrada for Multiple Near‑Term Catalysts and Upside Potential